| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma
|
Mao, Lili
|
|
|
175 |
C |
p. 125-135
|
artikel
|
| 2 |
Age trends in biliary tract cancer incidence by anatomical subtype: A Swedish cohort study
|
Rahman, Rithva
|
|
|
175 |
C |
p. 291-298
|
artikel
|
| 3 |
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases
|
Dutriaux, Caroline
|
|
|
175 |
C |
p. 254-262
|
artikel
|
| 4 |
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
|
Climent, Miguel A.
|
|
|
175 |
C |
p. 110-119
|
artikel
|
| 5 |
A risk stratification model for toxicities in phase 1 immunotherapy trials
|
Hernando-Calvo, Alberto
|
|
|
175 |
C |
p. 11-18
|
artikel
|
| 6 |
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
|
Müller-Jensen, Leonie
|
|
|
175 |
C |
p. 224-235
|
artikel
|
| 7 |
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
|
Meynard, Lucie
|
|
|
175 |
C |
p. 43-53
|
artikel
|
| 8 |
Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands
|
Kregting, Lindy M.
|
|
|
175 |
C |
p. 180-186
|
artikel
|
| 9 |
Corrigendum to ‘p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib’[Eur J of Cancer 55 (2016) 98–110]
|
Krayem, Mohammad
|
|
|
175 |
C |
p. 336-338
|
artikel
|
| 10 |
Cost-effectiveness of programmed death ligand-1 (PD-L1) blockade in first-line for metastatic gastric/gastroesophageal junction cancer
|
Giuliani, Jacopo
|
|
|
175 |
C |
p. 193-195
|
artikel
|
| 11 |
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study
|
Lee, Lennard Y.W.
|
|
|
175 |
C |
p. 1-10
|
artikel
|
| 12 |
Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I–III
|
Wang, Yang
|
|
|
175 |
C |
p. 196-203
|
artikel
|
| 13 |
Cutaneous Merkel cell carcinoma (MCC): A report from the 16th Annual Meeting for Multicenter Merkel Interest Group – A supplementation to the new European guidelines 2022 on MCC
|
Minutilli, Ettore
|
|
|
175 |
C |
p. 107-109
|
artikel
|
| 14 |
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
|
Taieb, Julien
|
|
|
175 |
C |
p. 136-157
|
artikel
|
| 15 |
Effect of glioma-derived immunoglobulin on biological function of glioma cells
|
Lv, Jiaoyun
|
|
|
175 |
C |
p. 86-98
|
artikel
|
| 16 |
Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review
|
ter Maat, Laurens S.
|
|
|
175 |
C |
p. 60-76
|
artikel
|
| 17 |
Immune checkpoint blockade for organ-transplant recipients with cancer: A review
|
Rünger, Alessandra
|
|
|
175 |
C |
p. 326-335
|
artikel
|
| 18 |
Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’
|
Langenberg, Karin P.S.
|
|
|
175 |
C |
p. 311-325
|
artikel
|
| 19 |
Incidence and survival of paediatric renal tumours in the Netherlands between 1990 and 2014
|
Schulpen, Maya
|
|
|
175 |
C |
p. 282-290
|
artikel
|
| 20 |
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study
|
Lepage, Côme
|
|
|
175 |
C |
p. 31-40
|
artikel
|
| 21 |
Maximal surgical tumour load reduction in immune-checkpoint inhibitor naïve patients with melanoma brain metastases correlates with prolonged survival
|
Voglis, Stefanos
|
|
|
175 |
C |
p. 158-168
|
artikel
|
| 22 |
Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review
|
Tesileanu, C. Mircea S.
|
|
|
175 |
C |
p. 214-223
|
artikel
|
| 23 |
Near-tetraploid T-cell acute lymphoblastic leukaemia in childhood: Results of the AIEOP-BFM ALL studies
|
Ceppi, Francesco
|
|
|
175 |
C |
p. 120-124
|
artikel
|
| 24 |
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters
|
Rimini, Margherita
|
|
|
175 |
C |
p. 299-310
|
artikel
|
| 25 |
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4
|
Xu, Binghe
|
|
|
175 |
C |
p. 236-245
|
artikel
|
| 26 |
PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK)
|
Lorenzen, Sylvie
|
|
|
175 |
C |
p. 99-106
|
artikel
|
| 27 |
Primary lung carcinoma in children and adolescents: An analysis of the European Cooperative Study Group on Paediatric Rare Tumours (EXPeRT)
|
Abele, Michael
|
|
|
175 |
C |
p. 19-30
|
artikel
|
| 28 |
RANKL inhibition for giant cell lesions of the jaw: A retrospective cohort analysis
|
Schreuder, Willem H.
|
|
|
175 |
C |
p. 263-273
|
artikel
|
| 29 |
Re: Chemotherapy in patients with localized angiosarcoma of any site. A retrospective European study
|
Cren, Pierre-Yves
|
|
|
175 |
C |
p. 41-42
|
artikel
|
| 30 |
Relapsing pediatric non-rhabdomyosarcoma soft tissue sarcomas: The impact of routine imaging surveillance on early detection and post-relapse survival
|
Morosi, Carlo
|
|
|
175 |
C |
p. 274-281
|
artikel
|
| 31 |
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
|
Fulgenzi, Claudia Angela Maria
|
|
|
175 |
C |
p. 204-213
|
artikel
|
| 32 |
Selecting patients with HER2-low breast cancer: Getting out of the tangle
|
Baez-Navarro, Ximena
|
|
|
175 |
C |
p. 187-192
|
artikel
|
| 33 |
Survival trends in solid cancers in the Nordic countries through 50 years
|
Hemminki, Janne
|
|
|
175 |
C |
p. 77-85
|
artikel
|
| 34 |
Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer
|
Vliek, Sonja B.
|
|
|
175 |
C |
p. 169-179
|
artikel
|
| 35 |
The need for a comprehensive and integrated approach to lung cancer policy in Europe
|
Racovita, Monica
|
|
|
175 |
C |
p. 54-59
|
artikel
|
| 36 |
Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population
|
Vic, Samuel
|
|
|
175 |
C |
p. 246-253
|
artikel
|
Tijdschrift beschrijving